Abstract 102P
Background
PROMETCO was the first international, prospective, real-world (RW) study (NCT03935763) to investigate the continuum of care in pts with mCRC and to provide RW survival evidence. Here we look at the UK cohort.
Methods
Adult mCRC pts who have had two disease progressions since mCRC diagnosis and willing to receive subsequent treatment were included. Baseline demographic, treatment patterns and molecular data for the full UK cohort were analysed. Endpoint data including OS and progression-free survival (PFS; defined as start of treatment until progressive disease, death or start of new treatment) were analysed for those patients who had completed the study by July 2023.
Results
A total of 76 pts from 10 UK sites were enrolled (Table). 39.5% of pts were RAS mutant; 34.2% RAS/BRAF wild type; 6.6% BRAF mutant. 59.2% had unknown microsatellite instability (MSI) status; 1.3% were MSI high; 9.2% were MSI low; 30.3% were microsatellite stable. Median time from mCRC diagnosis to enrolment was 21.6 mo. During their treatment, pts received fluoropyrimidine (98.7%), oxaliplatin (81.6%), irinotecan (98.7%), an anti-VEGF (2.6%) or an anti-EGFR antibody (44.7%), FTD/TPI (85.5%) or regorafenib (1.3%). As of July 2023, a total of 68 pts (89%) were included in the interim survival analysis. For those pts, mOS from mCRC diagnosis was 36.5 mo [95% CI 26.94;42.15], which is comparable to the global cohort; mOS from inclusion in PROMETCO (i.e., after second disease progression) was 5.5 mo; and mOS from start of 3rd-line treatment was 5.3 mo. Median PFS was 6.6 mo in 1st; 4.6 mo in 2nd; 2.4 mo in 3rd and 2.2 mo in 4th line. Table: 102P
Baseline characteristics (N=76)
| Median age (range), years | 65 (39-86) |
| Male sex, % | 60.5 |
| ECOG PS, % 0 / 1 / 2 | 27.6 / 65.8 / 6.6 |
| <3 metastatic sites, % | 92.1 |
| Synchronous metastases, % | 60.5 |
| Metastasis site, %: Liver / Lung / Other / Peritoneal carcinomatosis | 73.7 / 40.8 / 19.7 / 6.6 |
| Disease sidedness, % Right / Left / Rectum | 19.7 / 46.1 / 42.1 |
Conclusions
These data provide insights on UK pts characteristics, survival (comparable to the global cohort) and contemporary practice, reflecting UK current access to drugs and prescribing patterns.
Clinical trial identification
NCT03935763.
Legal entity responsible for the study
Servier Affaires Médicales, France.
Funding
Servier Affaires Médicales, France.
Disclosure
F.E. Marti Marti: Financial Interests, Personal, Invited Speaker: Servier; Financial Interests, Personal, Advisory Role: Servier. S.C. Lau: Non-Financial Interests, Personal, Invited Speaker, Honoraria: Servier. J.A. Bridgewater: Financial Interests, Personal, Invited Speaker: Incyte, Servier; Financial Interests, Personal, Advisory Role: Roche, Bayer, AstraZeneca, Incyte, Taiho, Basilea, BMS; Financial Interests, Institutional, Research Grant: Incyte. D. McLeod, M. Chauvet: Financial Interests, Personal, Full or part-time Employment: Servier. All other authors have declared no conflicts of interest.